Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay

1 week ago 4
ARTICLE AD BOX
Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said on Tuesday.
Read Entire Article
  1. Homepage
  2. Finance
  3. Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay

Related

Developers Say GPT-5 Is a Mixed Bag

Developers Say GPT-5 Is a Mixed Bag

13 minutes ago 0
Could Oracle become a $1 trillion company? This analyst charts the course.

Could Oracle become a $1 trillion company? This analyst char...

23 minutes ago 0
Intel’s stock is having a historic week. But would Trump’s aid just be lighting money on fire?

Intel’s stock is having a historic week. But would Trump’s a...

49 minutes ago 0

Trending

1. rockstar games gta 6
2. when we were young 2025
3. doge
4. sean kingston
5. super bowl 2026
6. liga española
7. clark hunt
8. pirates vs cubs
9. coven academy
10. elena rybakina

Popular

Netflix scuttles plans to add six previously announced games to its service

Netflix scuttles plans to add six previously announced games...

6 months ago 261
Can Pidcock win big & why did it end at Ineos?

Can Pidcock win big & why did it end at Ineos?

5 months ago 230
OpenAI co-founder John Schulman has left Anthropic after less than a year

OpenAI co-founder John Schulman has left Anthropic after les...

6 months ago 220
Steam will label early access games that haven't been updated in a year

Steam will label early access games that haven't been update...

6 months ago 219
Google's Magic Editor will watermark its AI-tweaked photos

Google's Magic Editor will watermark its AI-tweaked photos

6 months ago 207
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexa News 2025. All rights are reserved